Tailoring of an anti-diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in vitro evaluation of anti-hyperglycemic potential

Abdullah Shoaib, Sammia Shahid, Sana Mansoor, Mohsin Javed, Shahid Iqbal, Sajid Mahmood, Ali Bahadur, Fadi Jaber, Matar Alshalwi

Research output: Journal PublicationArticlepeer-review

6 Citations (Scopus)

Abstract

Diabetes is a serious health issue that can be a great risk factor related to numerous physical problems. A class of drugs “Gliflozin” especially Sodium Glucose Co. Transporter 2 was inhibited by a novel drug, which is known as “empagliflozin”. While ZnO nanoparticles (NPs) had considerable promise for combating diabetes, it was employed in the treatment and management of type-2 diabetes mellitus. The new drug empagliflozin was initially incorporated into Zinc Oxide NPs in this study using the surface physio-sorption technique, and the degree of drug adsorption was assessed using the HPLC method. The tailored product was characterized by using the FTIR, EDX, Ultraviolet–Visible, XRD and SEM techniques. With an average particle size of 17 nm, SEM revealed mono-dispersion of NPs and sphere-like form. The Freundlich isotherm model best fits and explains the data for the physio-sorption investigation, which examined adsorption capabilities using adsorption isotherms. The enzymes α-amylase and α-glucosidase, which are involved in the human metabolism of carbohydrates, were used in the in-vitro anti-diabetic assays. It was discovered that the composite showed the highest levels of 81.72 and 92.77% inhibition of -α-amylase and -glucosidase at an absolute concentration of 1000 μg per ml with IC50 values of 30.6 μg per ml and 72 μg per ml.

Original languageEnglish
Article number2499
JournalScientific Reports
Volume14
Issue number1
DOIs
Publication statusPublished - Dec 2024

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Tailoring of an anti-diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in vitro evaluation of anti-hyperglycemic potential'. Together they form a unique fingerprint.

Cite this